Evidence map›Paper›PMID 40087208›Full record

ArticleMolecular and cellular biochemistry2025

STAT1 increases the sensitivity of lung adenocarcinoma to carbon ion irradiation via HO-1-mediated ferroptosis.

Yanliang Chen, Dandan Wang, Hongtao Luo, Mingyu Tan, Qian Wang, Xun Wu, Tianqi Du, Qiuning Zhang, Wenzhen Yuan

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yanliang Chen *The First School of Clinical Medicine, Lanzhou University, Chengguan District, No. 1, Donggang West Road, Lanzhou, 730030, Gansu, China.ORCID http://orcid.org/0000-0003-0475-3774
Dandan Wang *The First School of Clinical Medicine, Lanzhou University, Chengguan District, No. 1, Donggang West Road, Lanzhou, 730030, Gansu, China.ORCID http://orcid.org/0000-0002-7293-2451
Hongtao LuoInstitute of Modern Physics, Chinese Academy of Sciences, Lanzhou, 730030, Gansu, China.ORCID http://orcid.org/0000-0002-2191-4552
Mingyu TanThe First School of Clinical Medicine, Lanzhou University, Chengguan District, No. 1, Donggang West Road, Lanzhou, 730030, Gansu, China.ORCID http://orcid.org/0009-0003-8505-0057
Qian WangThe First School of Clinical Medicine, Lanzhou University, Chengguan District, No. 1, Donggang West Road, Lanzhou, 730030, Gansu, China.ORCID http://orcid.org/0000-0003-3270-3248
Xun WuThe First School of Clinical Medicine, Lanzhou University, Chengguan District, No. 1, Donggang West Road, Lanzhou, 730030, Gansu, China.ORCID http://orcid.org/0009-0001-6500-3646
Tianqi DuThe First School of Clinical Medicine, Lanzhou University, Chengguan District, No. 1, Donggang West Road, Lanzhou, 730030, Gansu, China.ORCID http://orcid.org/0000-0002-1894-9607
Qiuning ZhangInstitute of Modern Physics, Chinese Academy of Sciences, Lanzhou, 730030, Gansu, China. zhangqn@impcas.ac.cn.ORCID http://orcid.org/0009-0006-6091-5976
Wenzhen YuanThe First School of Clinical Medicine, Lanzhou University, Chengguan District, No. 1, Donggang West Road, Lanzhou, 730030, Gansu, China. yuanwzh@lzu.edu.cn.ORCID http://orcid.org/0000-0003-4379-9898

Funding

Central guidance local science and technology development program Grant No. 24ZYQA029Gansu Province Project of Science and Technologies Grant No. 20JR10RA680, 22CX8JA149Lanzhou heavy Ion Accelerator High-end user Project HIR20GY007National Key Research and Development Program of China No.2022YFC2401500Science and Technology Project of Lanzhou City Grant No. 2023-1-9
6 · The paper itself

Abstract

Radiotherapy is a vital treatment agent for lung adenocarcinoma (LUAD) patients, while radioresistance remains a major factor in treatment failure. Here, we aimed to elucidate how signal transducer and activator of transcription 1 (STAT1) affected sensitivity to carbon ion irradiation for LUAD cells in vivo and in vitro. The results of colony formation, CCK-8, EdU, and calcein-AM/PI double-staining assays demonstrated that the overexpression of STAT1 markedly enhanced the inhibitory effect of carbon ion irradiation on the viability of LUAD cells (A549 and PC9 cells). Lactate dehydrogenase (LDH) leakage assays identified ferroptosis as the predominant form of cell death induced by STAT1 overexpression in LUAD cells. Meanwhile, the ferroptosis-related PCR array confirmed heme oxygenase 1 (HO-1) as a potential effector molecule of STAT1-induced ferroptosis. Mechanistically, STAT1 overexpression resulted in phosphorylation at the serine 727 residue, triggering the upregulation of HO-1 expression and subsequent labile iron pool (LIP) accumulation. This process amplified the Fenton reaction, leading to increased reactive oxygen species (ROS), lipid peroxides (LPO), and glutathione (GSH) depletion. HO-1 knockdown eliminated the ferroptosis induced by the overexpression of STAT1. Furthermore, in vivo experiments showed that STAT1 overexpression enhanced the effect of carbon ion irradiation in inhibiting the growth of subcutaneous tumors in nude mice. These findings provide the foundation for the development of the STAT1-HO-1 axis as a radiosensitization target for LUAD patients.

Indexed as

Adenocarcinoma of LungFerroptosisHeavy Ion RadiotherapyHeme Oxygenase-1Lung NeoplasmsNeoplasm ProteinsRadiation ToleranceSTAT1 Transcription FactorA549 CellsAnimalsCell Line, TumorHumansMiceMice, NudeReactive Oxygen SpeciesHeme Oxygenase-1HMOX1 protein, humanNeoplasm ProteinsReactive Oxygen SpeciesSTAT1 protein, humanSTAT1 Transcription FactorCarbon ion irradiationFerroptosisHO-1STAT1

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.